Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Profesionales de la salud / / / /
Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma
Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground Virtually all patients with low Grade Non-Hodgkin's Lymphoma (LG NHL) relapse. Relapsed or refractory LG NHL is very difficult to treat, as...
Duration of Molecular Remission in Patients with Acute Promyelocytic Leukemia (APML) Treated Primarily with Arsenic Tri-oxide
Presenter: B GeorgPresenter's Affiliation: Christian Medical College; Vellore, IndiaType of Session: PosterBackground Arsenic trioxide (As2O3) has been shown to be very effective for the treatment of APML. Most data has been with relapsed disease....
High Response Rates and Durable Remissions in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma Treated with Tositumomab and Iodine I-131 Tositumomab (Bexxar)
Presenter: Mark S. KaminskiPresenter's Affiliation: University of MichiganType of Session: PosterBackground I-131 Tositumomab is a monoclonal murine antibody directed against the CD20 cell surface protein present on most lymphocytes, including most...
Intermediate Dose Melphalan for de novo Multiple Myeloma gives high complete response rate and durable long term survival
Presenter: Mathew StreetlyPresenter's Affiliation: Queen Elizabeth Hospital, Woolwich, UKType of Session: PosterBackground Multiple Myeloma remains a disease with extremely high recurrence rates even after agressive chemotherapy. Oral Melphalan has...
Long Term Follow Up of a Phase II study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma (NHL)
Presenter: J.M. VosePresenter's Affiliation: University of Nebraska Medical CenterType of Session: PosterBackground Standard therapy for NHL is combination chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) Rituxan, a...
Oral Fludarabine phosphate as first-line treatment of chronic lymphocytic leukemia
Presenter: Jean-Francois RossiPresenter's Affiliation: CHU; Montpellier, FranceType of Session: PosterBackground Fludarabine phosphate is a nucleotide analog of arabinoside which has achieved overall response rates (ORR) of 63-70% in previously...
Phase I-II study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia
Presenter: Kanti R. RaiPresenter's Affiliation: Long Island Jewish Medical CenterType of Session: PosterBackground Chronic Lymphocytic Leukemia (CLL) is the most common chronic leukemia in adults. It's course is usually slow and insiduous however...
Preliminary Report of a Phase II Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarag)Given in Combination with Cytarabine in Patients with Acute Myelogenous Leukemia
Presenter: Michele BaccaraniPresenter's Affiliation: Ospedale S. Orsola; Bologna, ItalyType of Session: PosterBackground Gemtuzumab has been approved in the United States for the treatment of patients aged sixty and above with CD33+ AML in first...
Prevalence and Management of Anemia in Patients with Hematologic Malignancies and Solid Tumors: Results from the European Cancer Anemia Survey (ECAS)
Presenter: Heinz LudwigPresenter's Affiliation: ECAS Advisory BoardType of Session: PosterBackground Anemia (hgb Large randomized trials show that correction of anemia leads to symptom improvement and improved quality of life (QOL). ...
Quality of Life, Blood Transfusions, and Toxicity, in Anemic Patients with Advanced Cancer Receiving Weekly Erythropoietin While on Chemotherapy: Results from a Phase III Randomized Double-Blind Placebo-Controlled Study.
Presenter: Jeff A. SloanPresenter's Affiliation: Mayo ClinicType of Session: PosterBackground Anemia is obviously a large problem in the population of patients who are receiving chemotherapy. This anemia is likely amplified in those patients with...
Rituximab Treatment Failures: Tositumomab and Iodine I-131 Tositumomab (Bexxar) Can Produce Meaningful Durable Responses
Presenter: Sandra J. HorningPresenter's Affiliation: Stanford UniversityType of Session: PosterBackground Rituxan is a chimeric monoclonal antibody (MAb)directed against the CD20 cell surface protein. It effected a 50% overall response rate in the...
Zevalin Radioimmunotherapy is Not Associated with an Increased Incidence of Secondary Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML)
Presenter: M.S. CzuczmanPresenter's Affiliation: Roswell Park Cancer InstituteType of Session: PosterBackground Zevalin is an anti-CD 20 monoclonal antibody with bonded Yttrium-90, making it a radioimmunotherapy. It is being used more commonly in...
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults